Sedative and cardiopulmonary effects of dexmedetomidine infusions randomly receiving, or not, butorphanol in standing horses.

The research investigated the sedative and cardiopulmonary effects of dexmedetomidine, either alone or combined with butorphanol, on standing horses. It was found that both methods yielded clinically sufficient sedation for approximately 30 minutes, with notable reductions in response to tactile and auditory stimuli, as well as typical changes in cardiopulmonary activities.

Research Design

• The study was a randomized, crossover trial involving six healthy adult horses. It aimed to establish the various effects of dexmedetomidine (DEX) either alone or combined with butorphanol (BUT) when given continuously to standing horses.
• DEX and DEX/BUT were administered in specific quantities with the goal of determining their sedative and cardiopulmonary effects. As such, doses of DEX (3.5 µg/kg initially + 5 µg/kg/hour continuously), and a combination of DEX/BUT (dexmedetomidine at the rate of 3.5 µg/kg at first + 3.5 µg/kg/hour continuously and butorphanol at 20 µg/kg initially + 24 µg/kg/hour continuously) were utilized.

Data Gathering and Analysis

• Several observations and measurements were conducted before, during, and after the infusions, including head height above ground, ataxia, responses to tactile and auditory stimuli, and cardiopulmonary variables. These measurements were carried out at intervals (5/15/30/60/90 minutes) during infusion and after it stopped (15/30/60 minutes).
• The study employed statistical tests such as the repeated measures analysis of variance paired with the Tukey-Kramer test, primarily for cardiopulmonary values and head height reduction, and non-parametric methods such as Friedman’s and Dunn’s for non-parametric data.

Research Findings

• The study found that the most substantial reduction in head height above ground occurred within 15 minutes, amounting to 54 per cent for DEX and 58 per cent for DEX/BUT infusions. At the same time, ataxia or loss of full control of bodily movements was observed for 15 minutes under both treatments.
• The responses to tactile and auditory stimuli were significantly diminished for half an hour for both treatments. In the DEX administered horses, the auditory response was reduced up to 60 minutes.
• Cardiopulmonary effects typical of α-agonists were observed in all horses. Still, there were no discernable differences in these effects between horses that received only DEX and those that received the DEX/BUT combination.
• At the used doses and rates, both DEX and DEX/BUT succeeded in providing clinically decent sedation for around 30 minutes in the horses.